Less than a year after garnering the first anti-CLDN18.2 approval in the U.S., Astellas Pharma is not resting on its laurels.

The startup is the latest beneficiary of investors’ appetite for protein-degrading technology, which offers a way to reach ...

It’s GlycoEra’s time to shine. The biotech has closed a series B fundraise clocking in at $130 million, with the funds set to ...

In 2025, the global proteose peptone market is anticipated to be worth USD 151.4 million, with projections indicating a rise ...

ProteinQure raises $11M Series A led by Heron Rock to advance PQ203, a peptide-drug conjugate for triple-negative breast ...

AbbVie (NYSE: ABBV) in partnership with the University of Toronto's SpinUp, are pleased to announce Neuropeutics Inc as the ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by ...

The global protein expression market growth forecasted to transform from USD 3.41 billion in 2024 to USD 4.82 billion by 2029 ...

Cvictus recently received a $1.7 million grant from the Bill & Melinda Gates Foundation to scale its technology.

At the recent F&A Next conference in Wageningen, the Feike Sijbesma Sustainable Innovation Award 2025 was granted to two ...